Drugmaker Merck's first-quarter revenue rose 6 percent, driven by a huge jump in sales of cancer blockbuster Keytruda, but a $1.4 billion charge for starting a research partnership with Japanese drugmaker Eisai dragged down profits by more than half.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,